{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:05:28Z","timestamp":1792598728936,"version":"4.5.0"},"reference-count":45,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2022.13613","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:22:06Z","timestamp":1669310526000},"source":"Crossref","is-referenced-by-count":25,"title":["Effects of BRAF V600E and NRAS mutational status on the progression\u2011free survival and clinicopathological characteristics of patients with melanoma"],"prefix":"10.3892","volume":"25","author":[{"given":"Tatjana","family":"Zablocka","sequence":"first","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Latvia, LV\u20111004 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madara","family":"Kreismane","sequence":"additional","affiliation":[{"name":"Department of Cancer Research, Latvian Biomedical Research and Study Centre, LV\u20111067 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dace","family":"Pjanova","sequence":"additional","affiliation":[{"name":"Department of Cancer Research, Latvian Biomedical Research and Study Centre, LV\u20111067 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergejs","family":"Isajevs","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Latvia, LV\u20111004 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"key20230111131702_b1-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.3390\/ijms21103535","article-title":"Current molecular markers of melanoma and treatment targets","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20230111131702_b2-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"e2020033","DOI":"10.5826\/dpc.1003a33","article-title":"Melanoma epidemiology and early detection in Europe: Diversity and disparities","volume":"10","author":"Forsea","year":"2020","journal-title":"Dermatol Pract Concept"},{"key":"key20230111131702_b3-ol-25-01-13613","volume-title":"WHO Classification of Skin Tumours","author":"Elder","year":"2018","edition":"4th edition"},{"key":"key20230111131702_b4-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3109\/07853890.2016.1145795","article-title":"Melanoma screening: A plan for improving early detection","volume":"48","author":"Shellenberger","year":"2016","journal-title":"Ann Med"},{"key":"key20230111131702_b5-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00428-013-1526-x","article-title":"Tissue prognostic biomarkers in primary cutaneous melanoma","volume":"464","author":"Mandal\u00e0","year":"2014","journal-title":"Virchows Arch"},{"key":"key20230111131702_b6-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: Detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"key20230111131702_b7-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment","volume":"26","author":"Fong","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20230111131702_b8-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"key20230111131702_b9-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20230111131702_b10-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20230111131702_b11-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"key20230111131702_b12-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"14759","DOI":"10.18632\/oncotarget.14736","article-title":"Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"key20230111131702_b13-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front Immunol"},{"key":"key20230111131702_b14-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3892\/mco.2021.2417","article-title":"Addressing the importance of melanoma tumor-infiltrating lymphocytes in disease progression and clinicopathological characteristics","volume":"15","author":"Zablocka","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"key20230111131702_b15-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"key20230111131702_b16-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00428-017-2113-3","article-title":"Molecular genetic and immunotherapeutic targets in metastatic melanoma","volume":"471","author":"Melis","year":"2017","journal-title":"Virchows Arch"},{"key":"key20230111131702_b17-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/jdv.12910","article-title":"Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma","volume":"29","author":"Pracht","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20230111131702_b18-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/0284186X.2020.1747636","article-title":"BRAF mutational status as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis","volume":"59","author":"Ny","year":"2020","journal-title":"Acta Oncol"},{"key":"key20230111131702_b19-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing","volume":"6","author":"Rose","year":"2006","journal-title":"Melanoma Res"},{"key":"key20230111131702_b20-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"36130","DOI":"10.18632\/oncotarget.9143","article-title":"Which melanoma patient carries a BRAF-mutation? A comparison of predictive models","volume":"7","author":"Eigentler","year":"2016","journal-title":"Oncotarget"},{"key":"key20230111131702_b21-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"key20230111131702_b22-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20230111131702_b23-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11864-021-00818-3","article-title":"BRAF heterogeneity in melanoma","volume":"22","author":"Ito","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"key20230111131702_b24-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jid.2018.12.033","article-title":"Molecular genomic profiling of melanocytic nevi","volume":"139","author":"Colebatch","year":"2019","journal-title":"J Invest Dermatol"},{"key":"key20230111131702_b25-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/PAI.0000000000000071","article-title":"BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma","volume":"23","author":"Chiappetta","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"key20230111131702_b26-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","article-title":"Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma","volume":"1","author":"Thomas","year":"2015","journal-title":"JAMA Oncol"},{"key":"key20230111131702_b27-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"key20230111131702_b28-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"631","DOI":"10.4149\/neo_2018_181006N740","article-title":"Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients","volume":"66","author":"Tas","year":"2019","journal-title":"Neoplasma"},{"key":"key20230111131702_b29-ol-25-01-13613","first-page":"225","article-title":"Clinicopathological characteristics of BRAF V600E mutated melanomas in the dalmatian region of croatia","volume":"27","author":"Bezi\u0107","year":"2019","journal-title":"Acta Dermatovenerol Croat"},{"key":"key20230111131702_b30-ol-25-01-13613","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5826\/dpc.0901a13","article-title":"BRAF mutation status in primary, recurrent, and metastatic malignant melanoma and its relation to histopathological parameters","volume":"9","author":"Spathis","year":"2019","journal-title":"Dermatol Pract Concept"},{"key":"key20230111131702_b31-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","article-title":"Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma","volume":"72","author":"Kim","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key20230111131702_b32-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/PDM.0b013e318298c1d9","article-title":"Clinicopathologic findings and BRAF mutation in cutaneous melanoma in young adults","volume":"22","author":"Estrozi","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"key20230111131702_b33-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.prp.2015.03.005","article-title":"Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma","volume":"211","author":"Aksenenko","year":"2015","journal-title":"Pathol Res Pract"},{"key":"key20230111131702_b34-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molonc.2007.12.003","article-title":"Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site","volume":"1","author":"Platz","year":"2008","journal-title":"Mol Oncol"},{"key":"key20230111131702_b35-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.humpath.2016.07.008","article-title":"Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma","volume":"57","author":"Weiss","year":"2016","journal-title":"Hum Pathol"},{"key":"key20230111131702_b36-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/PAT.0000000000000314","article-title":"FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor","volume":"47","author":"Leslie","year":"2015","journal-title":"Pathology"},{"key":"key20230111131702_b37-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"key20230111131702_b38-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta-analysis","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"key20230111131702_b39-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1371\/journal.pone.0000236","article-title":"B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis","volume":"2","author":"Ugurel","year":"2007","journal-title":"PLoS One"},{"key":"key20230111131702_b40-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","article-title":"Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma","volume":"24","author":"Devitt","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"key20230111131702_b41-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care","volume":"17","author":"Heppt","year":"2017","journal-title":"BMC Cancer"},{"key":"key20230111131702_b42-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20230111131702_b43-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bjd.12140","article-title":"Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: A single-centre investigation of 141 patients","volume":"168","author":"Schlaak","year":"2013","journal-title":"Br J Dermatol"},{"key":"key20230111131702_b44-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1002\/cncr.28306","article-title":"Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma","volume":"119","author":"Bucheit","year":"2013","journal-title":"Cancer"},{"key":"key20230111131702_b45-ol-25-01-13613","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40257-017-0292-y","article-title":"MEK inhibitors in the treatment of metastatic melanoma and solid tumors","volume":"18","author":"Grimaldi","year":"2017","journal-title":"Am J Clin Dermatol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:50:16Z","timestamp":1728481816000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2022.13613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,24]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2022.13613","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"article-number":"27"}}